ROSUVASTATIN CALCIUM tablet, film coated

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
ROSUVASTATIN CALCIUM (UNII: 83MVU38M7Q) (ROSUVASTATIN - UNII:413KH5ZJ73)
Available from:
REMEDYREPACK INC.
INN (International Name):
ROSUVASTATIN CALCIUM
Composition:
ROSUVASTATIN 20 mg
Administration route:
ORAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Rosuvastatin tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. Rosuvastatin tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). Rosuvastatin tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias. Rosuvastatin tablets are contraindicated in the following conditions:    - Patients with a known hypersensitivity to an
Product summary:
Rosuvastatin Tablets USP 5 mg are pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘29’ on the other side.          Bottles of 30                              NDC 57237-168-30          Bottles of 90                              NDC 57237-168-90          Bottles of 500                             NDC 57237-168-05          Bottles of 1,000                          NDC 57237-168-99           Rosuvastatin Tablets USP 10 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘30’ on the other side.          Bottles of 30                              NDC 57237-169-30             Bottles of 90                              NDC 57237-169-90          Bottles of 500                             NDC 57237-169-05          Bottles of 1,000                          NDC 57237-169-99 Rosuvastatin Tablets USP  20 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘31’ on the other side.          Bottles of 30                              NDC 57237-170-30          Bottles of 90                              NDC 57237-170-90          Bottles of 500                             NDC 57237-170-05          Bottles of 1,000                          NDC 57237-170-99        Rosuvastatin Tablets USP  40 mg are pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘32’ on the other side.             Bottles of 30                              NDC 57237-171-30          Bottles of 90                              NDC 57237-171-90          Bottles of 500                             NDC 57237-171-05          Bottles of 1,000                          NDC 57237-171-99 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Authorization status:
Abbreviated New Drug Application
Authorization number:
70518-0002-0

ROSUVASTATIN CALCIUM- rosuvastatin calcium tablet, film coated

REMEDYREPACK INC.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and

effectively. See full prescribing information for ROSUVASTATIN TABLETS.

ROSUVASTATIN tablets, for oral use

Initial U.S. Approval: 2003

INDICATIONS AND USAGE

Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for:

adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3)

adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4)

adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5)

Limitations of use ( 1.8): Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias.

DOSAGE AND ADMINISTRATION

Rosuvastatin tablets can be taken with or without food, at any time of day. (2.1)

Dose range: 5 to 40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg. (2.1)

Adult HoFH : Starting dose 20 mg/day. (2.1)

DOSAGE FORMS AND STRENGTHS

Tablets: 5 mg, 10 mg, 20 mg, and 40 mg (3)

CONTRAINDICATIONS

Known hypersensitivity to product components (4)

Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4)

Pregnancy ( 4, 8.1, 8.3)

Lactation ( 4, 8.2)

WARNINGS AND PRECAUTIONS

Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with use of 40 mg dose, advanced

age (≥65), hypothyroidism, renal impairment, and combination use with cyclosporine, atazanavir/ritonavir,

lopinavir/ritonavir, or simeprevir. Cases of myopathy and rhabdomyolysis with acute renal failure secondary to

myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent

muscle pain, tenderness, or weakness and discontinue rosuvastatin if signs or symptoms appear. (5.1, 7.5, 7.6)

Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Perform liver enzyme tests

before initiating therapy and as clinically indicated thereafter. (5.2)

ADVERSE REACTIONS

Most frequent adverse reactions (rate ≥2%) are headache, myalgia, abdominal pain, asthenia, and nausea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-

FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1,

7.1, 12.3)

Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1,

7.2)

Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit

rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)

Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets.

Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. (5.3, 7.4)

Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the

risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuvastatin. (5.1, 7.5, 7.6)

USE IN SPECIFIC POPULATIONS

Females of reproductive potential: Advise females of reproductive potential to use effective contraception during

treatment with rosuvastatin ( 8.3)

Severe renal impairment (not on hemodialysis): Starting dose is 5 mg, not to exceed 10 mg. ( 2.5, 5.1, 8.6)

Asian population: Consider 5 mg starting dose. ( 2.3, 8.8)

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR

(rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product

is not labeled with that pediatric information.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 2/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.3 Hypertriglyceridemia

1.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

1.5 Adult Patients with Homozygous Familial Hypercholesterolemia

1.8 Limitations of Use

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

2.3 Dosing in Asian Patients

2.4 Use with Concomitant Therapy

2.5 Dosing in Patients with Severe Renal Impairment

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Skeletal Muscle Effects

5.2 Liver Enzyme Abnormalities

5.3 Concomitant Coumarin Anticoagulants

5.4 Proteinuria and Hematuria

5.5 Endocrine Effects

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Cyclosporine

7.2 Gemfibrozil

7.3 Protease Inhibitors

7.4 Coumarin Anticoagulants

7.5 Niacin

7.6 Fenofibrate

7.7 Colchicine

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

8.8 Asian Patients

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.5 Pharmacogenomics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

14.3 Hypertriglyceridemia

14.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

14.5 Homozygous Familial Hypercholesterolemia

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

1.3 Hypertriglyceridemia

Rosuvastatin tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with

hypertriglyceridemia.

1.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

Rosuvastatin tablets are indicated as an adjunct to diet for the treatment of adult patients with primary

dysbetalipoproteinemia (Type III Hyperlipoproteinemia).

1.5 Adult Patients with Homozygous Familial Hypercholesterolemia

Rosuvastatin tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL

apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult

patients with homozygous familial hypercholesterolemia.

1.8 Limitations of Use

Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias.

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

The dose range for rosuvastatin tablets in adults is 5 to 40 mg orally once daily. The usual starting dose

is 10 to 20 mg once daily. The usual starting dose in adult patients with homozygous familial

hypercholesterolemia is 20 mg once daily.

The maximum rosuvastatin tablets dose of 40 mg should be used only for those patients who have not

achieved their LDL-C goal utilizing the 20 mg dose [see Warnings and Precautions (5.1)].

Rosuvastatin tablets can be administered as a single dose at any time of day, with or without food. The

tablet should be swallowed whole.

When initiating rosuvastatin tablets therapy or switching from another HMG-CoA reductase inhibitor

therapy, the appropriate rosuvastatin tablets starting dose should first be utilized, and only then titrated

according to the patient’s response and individualized goal of therapy.

After initiation or upon titration of rosuvastatin tablets, lipid levels should be analyzed within 2 to 4

weeks and the dosage adjusted accordingly.

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s

Sections or subsections omitted from the full prescribing information are not listed.

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

2.3 Dosing in Asian Patients

In Asian patients, consider initiation of rosuvastatin tablets therapy with 5 mg once daily due to

increased rosuvastatin plasma concentrations. The increased systemic exposure should be taken into

consideration when treating Asian patients not adequately controlled at doses up to 20 mg/day [see Use

in Specific Populations (8.8) and Clinical Pharmacology (12.3)] .

2.4 Use with Concomitant Therapy

Patients taking cyclosporine

The dose of rosuvastatin tablets should not exceed 5 mg once daily [see Warnings and Precautions (5.1),

Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Patients taking gemfibrozil

Avoid concomitant use of rosuvastatin tablets with gemfibrozil. If concomitant use cannot be avoided,

initiate rosuvastatin tablets at 5 mg once daily. The dose of rosuvastatin tablets should not exceed 10 mg

once daily [see Warnings and Precautions (5.1), Drug Interactions (7.2) and Clinical Pharmacology

(12.3)].

Patients taking atazanavir and ritonavir, lopinavir and ritonavir, or simeprevir

Initiate rosuvastatin tablets therapy with 5 mg once daily. The dose of rosuvastatin tablets should not

exceed 10 mg once daily [see Warnings and Precautions (5.1), Drug Interactions (7.3) and Clinical

Pharmacology (12.3)].

2.5 Dosing in Patients with Severe Renal Impairment

For patients with severe renal impairment (CL

<30 mL/min/1.73 m

) not on hemodialysis, dosing of

rosuvastatin tablets should be started at 5 mg once daily and not exceed 10 mg once daily [see Use in

Specific Populations (8.6) and Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

Rosuvastatin Tablets USP are available containing 5 mg, 10 mg, 20 mg or 40 mg of rosuvastatin.

5 mg: Pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘29’ on the

other side.

10 mg: Pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘30’ on the other

side.

20 mg: Pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘31’ on the other

side.

40 mg: Pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘32’ on the

other side.

4 CONTRAINDICATIONS

Rosuvastatin tablets are contraindicated in the following conditions:

Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions

including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin [see Adverse

Reactions (6.1)].

Patients with active liver disease, which may include unexplained persistent elevations of hepatic

transaminase levels [see Warnings and Precautions (5.2)].

Pregnancy [see Use in Specific Populations (8.1, 8.3)].

Lactation. Limited data indicate that rosuvastatin is present in human milk. Because statins have the

potential for serious adverse reactions in nursing infants, women who require rosuvastatin treatment

should not breastfeed their infants [see Use in Specific Populations (8.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Skeletal Muscle Effects

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have

been reported with HMG-CoA reductase inhibitors, including rosuvastatin. These risks can

occur at any dose level, but are increased at the highest dose (40 mg).

Rosuvastatin should be prescribed with caution in patients with predisposing factors for myopathy (e.g.,

age ≥ 65 years, inadequately treated hypothyroidism, renal impairment).

The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration

of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine,

atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir [see Dosage and Administration (2) and Drug

Interactions (7)] . Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA

reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be

exercised when prescribing rosuvastatin with colchicine [see Drug Interactions (7.7)] .

Rosuvastatin therapy should be discontinued if markedly elevated creatine kinase levels occur or

myopathy is diagnosed or suspected. Rosuvastatin therapy should also be temporarily withheld in any

patient with an acute, serious condition suggestive of myopathy or predisposing to the development of

renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery,

trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).

There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune

myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and

elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy

showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive

agents.

All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness,

or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist

after discontinuing rosuvastatin.

5.2 Liver Enzyme Abnormalities

It is recommended that liver enzyme tests be performed before the initiation of rosuvastatin, and if signs

or symptoms of liver injury occur.

Increases in serum transaminases [AST (SGOT) or ALT (SGPT)] have been reported with HMG-CoA

reductase inhibitors, including rosuvastatin. In most cases, the elevations were transient and resolved or

improved on continued therapy or after a brief interruption in therapy. There were two cases of

jaundice, for which a relationship to rosuvastatin therapy could not be determined, which resolved after

discontinuation of therapy. There were no cases of liver failure or irreversible liver disease in these

trials.

In a pooled analysis of placebo-controlled trials, increases in serum transaminases to >3 times the upper

limit of normal occurred in 1.1% of patients taking rosuvastatin versus 0.5% of patients treated with

limit of normal occurred in 1.1% of patients taking rosuvastatin versus 0.5% of patients treated with

placebo.

There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking

statins, including rosuvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia

or jaundice occurs during treatment with rosuvastatin, promptly interrupt therapy. If an alternate etiology

is not found, do not restart rosuvastatin.

Rosuvastatin should be used with caution in patients who consume substantial quantities of alcohol

and/or have a history of chronic liver disease [see Clinical Pharmacology (12.3)]. Active liver disease,

which may include unexplained persistent transaminase elevations, is a contraindication to the use of

rosuvastatin [see Contraindications (4)] .

5.3 Concomitant Coumarin Anticoagulants

Caution should be exercised when anticoagulants are given in conjunction with rosuvastatin because

of its potentiation of the effect of coumarin-type anticoagulants in prolonging the prothrombin time/INR.

In patients taking coumarin anticoagulants and rosuvastatin concomitantly, INR should be determined

before starting rosuvastatin and frequently enough during early therapy to ensure that no significant

alteration of INR occurs [see Drug Interactions (7.4)].

5.4 Proteinuria and Hematuria

In the rosuvastatin clinical trial program, dipstick-positive proteinuria and microscopic hematuria were

observed among rosuvastatin treated patients. These findings were more frequent in patients taking

rosuvastatin 40 mg, when compared to lower doses of rosuvastatin or comparator HMG-CoA reductase

inhibitors, though it was generally transient and was not associated with worsening renal function.

Although the clinical significance of this finding is unknown, a dose reduction should be considered

for patients on rosuvastatin therapy with unexplained persistent proteinuria and/or hematuria during

routine urinalysis testing.

5.5 Endocrine Effects

Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase

inhibitors, including rosuvastatin. Based on clinical trial data with rosuvastatin, in some instances these

increases may exceed the threshold for the diagnosis of diabetes mellitus [see Adverse Reactions (6.1)].

Although clinical studies have shown that rosuvastatin alone does not reduce basal plasma cortisol

concentration or impair adrenal reserve, caution should be exercised if rosuvastatin is administered

concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such

as ketoconazole, spironolactone, and cimetidine.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the label:

Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [see

Warnings and Precautions (5.1)]

Liver enzyme abnormalities [see Warnings and Precautions (5.2)]

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates

observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of

another drug and may not reflect the rates observed in clinical practice.

In the rosuvastatin controlled clinical trials database (placebo or active-controlled) of 5394 patients

with a mean treatment duration of 15 weeks, 1.4% of patients discontinued due to adverse reactions.

The most common adverse reactions that led to treatment discontinuation were:

myalgia

abdominal pain

nausea

The most commonly reported adverse reactions (incidence ≥ 2%) in the rosuvastatin controlled clinical

trial database of 5394 patients were:

headache

myalgia

abdominal pain

asthenia

nausea

Adverse reactions reported in ≥ 2% of patients in placebo-controlled clinical studies and at a rate

greater than placebo are shown in Table 1. These studies had a treatment duration of up to 12 weeks.

Table 1. Adverse Reactions

Reported in ≥ 2% of Patients Treated with Rosuvastatin and >

Placebo in Placebo-Controlled Trials (% of Patients)

Adverse reactions by COSTART preferred term.

Advers e

Reactions

Rosuvastatin

5 mg

N=291

Rosuvastatin

10 mg

N=283

Rosuvastatin

20 mg

N=64

Ros uvas tatin

40 mg

N=106

Total

Rosuvastatin

5 mg to 40 mg

N=744

Placebo

N=382

Headache

Nausea

Myalgia

Asthenia

Constipation

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity

(including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory

abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria [see

Warnings and Precautions (5.4)]; elevated creatine phosphokinase, transaminases, glucose, glutamyl

transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.

In a clinical trial, involving 981 participants treated with rosuvastatin 40 mg (n=700) or placebo (n=281)

with a mean treatment duration of 1.7 years, 5.6% of subjects treated with rosuvastatin versus 2.8% of

placebo-treated subjects discontinued due to adverse reactions. The most common adverse reactions

that led to treatment discontinuation were: myalgia, hepatic enzyme increased, headache, and nausea.

Adverse reactions reported in ≥ 2% of patients and at a rate greater than placebo are shown in Table 2.

Table 2. Adverse Reactions

Reported in ≥ 2% of Patients Treated with Rosuvastatin and >

Placebo in a Trial (% of Patients)

Adverse reactions by MedDRA preferred term.

Frequency recorded as abnormal laboratory value.

Adverse Reactions

Rosuvastatin 40 mg

N=700

Placebo

N=281

Myalgia

12.7

12.1

Arthralgia

10.1

Headache

Dizziness

Increased CPK

Abdominal pain

ALT >3x ULN

In a clinical trial, 17,802 participants were treated with rosuvastatin 20 mg (n=8901) or placebo

(n=8901) for a mean duration of 2 years. A higher percentage of rosuvastatin-treated patients versus

placebo-treated patients, 6.6% and 6.2%, respectively, discontinued study medication due to an adverse

event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to

1

1

1

1

2

2

treatment discontinuation.

There was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin

(2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in

rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c

> 6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated

patients [see Warnings and Precautions (5.5)].

Adverse reactions reported in ≥ 2% of patients and at a rate greater than placebo are shown in Table 3.

Table 3. Adverse Reactions

Reported in ≥ 2% of Patients Treated with Rosuvastatin and >

Placebo in a Trial (% of Patients)

Treatment-emergent adverse reactions by MedDRA preferred term.

Adverse Reactions

Rosuvastatin

20 mg

N=8901

Placebo

N=8901

Myalgia

Arthralgia

Constipation

Diabetes mellitus

Nausea

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of rosuvastatin:

arthralgia, fatal and non-fatal hepatic failure, hepatitis, jaundice, thrombocytopenia, depression, sleep

disorders (including insomnia and nightmares), peripheral neuropathy, interstitial lung disease and

gynecomastia. Because these reactions are reported voluntarily from a population of uncertain size, it is

not always possible to reliably estimate their frequency or establish a causal relationship to drug

exposure.

There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see

Warnings and Precautions (5.1)] .

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness,

amnesia, memory impairment, and confusion) associated with statin use. These cognitive issues have

been reported for all statins. The reports are generally nonserious, and reversible upon statin

discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median

of 3 weeks).

7 DRUG INTERACTIONS

7.1 Cyclosporine

Cyclosporine increased rosuvastatin exposure and may result in increased risk of myopathy. Therefore,

in patients taking cyclosporine, the dose of rosuvastatin should not exceed 5 mg once daily [see Dosage

and Administration (2.4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.2 Gemfibrozil

Gemfibrozil significantly increased rosuvastatin exposure. Due to an observed increased risk of

myopathy/rhabdomyolysis, combination therapy with rosuvastatin and gemfibrozil should be avoided. If

used together, the dose of rosuvastatin should not exceed 10 mg once daily [see Clinical Pharmacology

(12.3)].

7.3 Protease Inhibitors

Coadministration of rosuvastatin with certain protease inhibitors has differing effects on rosuvastatin

1

1

exposure and may increase risk of myopathy. Simeprevir, which is a hepatitis C virus (HCV) protease

inhibitor, or combinations of atazanavir/ritonavir or lopinavir/ritonavir, which are HIV-1 protease

inhibitors, increase rosuvastatin exposure [see Table 4 – Clinical Pharmacology (12.3)] . For these

protease inhibitors, the dose of rosuvastatin should not exceed 10 mg once daily. The combinations of

fosamprenavir/ritonavir or tipranavir/ritonavir, which are HIV-1 protease inhibitors, produce little or no

change in rosuvastatin exposure. Caution should be exercised when rosuvastatin is coadministered with

protease inhibitors [see Dosage and Administration (2.4), Warnings and Precautions (5.1) and Clinical

Pharmacology (12.3)].

7.4 Coumarin Anticoagulants

Rosuvastatin significantly increased INR in patients receiving coumarin anticoagulants. Therefore,

caution should be exercised when coumarin anticoagulants are given in conjunction with rosuvastatin. In

patients taking coumarin anticoagulants and rosuvastatin concomitantly, INR should be determined

before starting rosuvastatin and frequently enough during early therapy to ensure that no significant

alteration of INR occurs [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

7.5 Niacin

The risk of skeletal muscle effects may be enhanced when rosuvastatin is used in combination with

lipid-modifying doses (≥1 g/day) of niacin; caution should be used when prescribing with rosuvastatin

[see Warnings and Precautions (5.1)].

7.6 Fenofibrate

When rosuvastatin was coadministered with fenofibrate, no clinically significant increase in the AUC of

rosuvastatin or fenofibrate was observed. Because it is known that the risk of myopathy during treatment

with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should

be used when prescribing fenofibrates with rosuvastatin [see Warnings and Precautions (5.1) and

Clinical Pharmacology (12.3)].

7.7 Colchicine

Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase

inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised

when prescribing rosuvastatin with colchicine [see Warnings and Precautions (5.1)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not been

established and there is no apparent benefit to therapy with rosuvastatin during pregnancy. Because

HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other

biologically active substances derived from cholesterol, rosuvastatin may cause fetal harm when

administered to pregnant women. Rosuvastatin should be discontinued as soon as pregnancy is

recognized [see Contraindications (4)] . Limited published data on the use of rosuvastatin are insufficient

to determine a drug-associated risk of major congenital malformations or miscarriage. In animal

reproduction studies, there were no adverse developmental effects with oral administration of

rosuvastatin during organogenesis at systemic exposures equivalent to a maximum recommended human

dose (MRHD) of 40 mg/day in rats or rabbits (based on AUC and body surface area, respectively). In

rats and rabbits, decreased pup/fetal survival occurred at 12 times and equivalent, respectively, to the

MRHD of 40 mg/day [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is

unknown. In the U.S. general population, the estimated background risk of major birth defects and

miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Human Data

Limited published data on rosuvastatin have not shown an increased risk of major congenital

malformations or miscarriage. Rare reports of congenital anomalies have been received following

intrauterine exposure to other statins. In a review of approximately 100 prospectively followed

pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies,

spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general

population. The number of cases is adequate to exclude a ≥3 to 4-fold increase in congenital anomalies

over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was

initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was

identified.

Animal Data

Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3%

and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage

dose on gestation day 16 in rats. A higher fetal tissue distribution (25% maternal plasma concentration)

was observed in rabbits after a single oral gavage dose of 1 mg/kg on gestation day 18.

Rosuvastatin administration did not indicate a teratogenic effect in rats at ≤25 mg/kg/day or in rabbits ≤3

mg/kg/day (doses equivalent to the MRHD of 40 mg/day based on AUC and body surface area,

respectively).

In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7

resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10

times the human exposure at the MRHD dose of 40 mg/day based on AUC).

In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day

21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD

of 40 mg/day based body surface area).

In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18,

decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the

MRHD of 40 mg/day based on body surface area).

8.2 Lactation

Risk Summary

Rosuvastatin use is contraindicated during breastfeeding [see Contraindications (4)] . Limited data

indicate that rosuvastatin is present in human milk. There is no available information on the effects of the

drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for

serious adverse reactions in a breastfed infant, advise patients that breastfeeding is not recommended

during treatment with rosuvastatin.

8.3 Females and Males of Reproductive Potential

Contraception

Rosuvastatin may cause fetal harm when administered to a pregnant woman [see Use in Specific

Populations (8.1)]. Advise females of reproductive potential to use effective contraception during

treatment with rosuvastatin.

8.4 Pediatric Use

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

8.5 Geriatric Use

Of the 10,275 patients in clinical studies with rosuvastatin, 3159 (31%) were 65 years and older, and

698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed

between these subjects and younger subjects, and other reported clinical experience has not identified

differences in responses between the elderly and younger patients, but greater sensitivity of some older

individuals cannot be ruled out.

Elderly patients are at higher risk of myopathy and rosuvastatin should be prescribed with caution in the

elderly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

8.6 Renal Impairment

Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr ≥ 30 mL/min/1.73 m

). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal

impairment (CLcr <30 mL/min/1.73 m

) who are not receiving hemodialysis and dose adjustment is

required [see Dosage and Administration (2.5), Warnings and Precautions (5.1) and Clinical

Pharmacology (12.3)].

8.7 Hepatic Impairment

Rosuvastatin is contraindicated in patients with active liver disease, which may include unexplained

persistent elevations of hepatic transaminase levels. Chronic alcohol liver disease is known to increase

rosuvastatin exposure; rosuvastatin should be used with caution in these patients [see Contraindications

(4), Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].

8.8 Asian Patients

Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to

rosuvastatin in Asian subjects when compared with Caucasian controls. Rosuvastatin dosage should be

adjusted in Asian patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE

There is no specific treatment in the event of overdose. In the event of overdose, the patient should be

treated symptomatically and supportive measures instituted as required. Hemodialysis does not

significantly enhance clearance of rosuvastatin.

11 DESCRIPTION

Rosuvastatin calcium is a synthetic lipid-lowering agent for oral administration.

The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-

[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt

with the following structural formula:

The empirical formula for rosuvastatin calcium is (C

Ca and the molecular weight is

1001.14. Rosuvastatin calcium USP is a white to off-white powder that is sparingly soluble in water

and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a

partition coefficient (octanol/water) of 0.13 at pH of 7.0.

Rosuvastatin tablets USP for oral administration contain 5 mg, 10 mg, 20 mg or 40 mg of rosuvastatin

and the following inactive ingredients: crospovidone, dibasic calcium phosphate anhydrous,

hypromellose, iron oxide red, lactose monohydrate, magnesium stearate, microcrystalline cellulose,

titanium dioxide, and triacetin.

Meets USP Dissolution Test-2.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme

that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In vivo

studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to

have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering.

In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it

increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of

LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of

VLDL and LDL particles.

12.2 Pharmacodynamics

Rosuvastatin dose dependently reduces elevated LDL-cholesterol and reduces total cholesterol and

triglycerides and increases HDL-cholesterol [see Clinical Studies (14)] . A therapeutic response to

rosuvastatin is evident within 1 week of commencing therapy and 90% of maximum response is usually

achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.

Individualization of drug dosage should be based on the therapeutic response [see Dosage and

Administration (2)] .

12.3 Pharmacokinetics

Abs orption

In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5

hours following oral dosing. Both C

and AUC increased in approximate proportion to rosuvastatin

dose. The absolute bioavailability of rosuvastatin is approximately 20%.

Administration of rosuvastatin with food did not affect the AUC of rosuvastatin.

The AUC of rosuvastatin does not differ following evening or morning drug administration.

Dis tribution

Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is

88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma

concentrations.

Elimination

Rosuvastatin is primarily eliminated by excretion in the feces. The elimination half-life of rosuvastatin

is approximately 19 hours.

Metabolism

Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as

metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by

cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has

approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent

compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is

accounted for by the parent compound.

Excretion

Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces

(90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route,

and 72% by the hepatic route.

Specific Populations

Racial or Ethnic Groups

A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics

among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies,

including one conducted in the U.S., have demonstrated an approximate 2-fold elevation in median

exposure (AUC and C

) in Asian subjects when compared with a Caucasian control group.

Male and Female Patients

There were no differences in plasma concentrations of rosuvastatin between men and women.

Pediatric use information for patients ages 8 to less than 10 years is approved for AstraZeneca’s

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

GeriatricPatients

There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly

populations (age ≥ 65 years).

Patients with Renal Impairment

Mild to moderate renal impairment (CL

≥ 30 mL/min/1.73 m

) had no influence on plasma

concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically

significant extent (about 3-fold) in patients with severe renal impairment (CL

< 30 mL/min/1.73 m

not receiving hemodialysis compared with healthy subjects (CL

> 80 mL/min/1.73 m

Hemodialysis

Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were

approximately 50% greater compared with healthy volunteer subjects with normal renal function.

Patients with Hepatic Impairment

In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly

increased.

In patients with Child-Pugh A disease, C

and AUC were increased by 60% and 5%, respectively, as

compared with patients with normal liver function. In patients with Child-Pugh B disease, C

AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.

Drug Interactions Studies

Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically

significant extent.

Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter

organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance

protein (BCRP). Concomitant administration of rosuvastatin with medications that are inhibitors of these

transporter proteins (e.g., cyclosporine, certain HIV protease inhibitors) may result in increased

rosuvastatin plasma concentrations [see Dosage and Administration (2.4) and Drug Interactions (7.1, 7.3)]

.

Table 4. Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure

Coadministered drug and dosing regimen

Rosuvastatin

Mean Ratio

(ratio with/without coadministered

drug)

No Effect = 1.0

Dose (mg)

Change in AUC

Change in C

Cyclosporine – stable dose required

(75 mg to 200 mg BID)

10 mg QD for 10

days

Atazanavir/ritonavir combination 300 mg/100

mg QD for 8 days

10 mg

Simeprevir 150 mg QD, 7 days

10 mg, single

dose

(2.3 to 3.4)

(2.6 to 3.9)

Lopinavir/ritonavir combination

400 mg/100 mg BID for 17 days

20 mg QD for 7

days

(1.7 to 2.6)

(3.4 to 6.4)

Gemfibrozil 600 mg BID for 7 days

80 mg

(1.6 to 2.2)

(1.8 to 2.7)

Eltrombopag 75 mg QD, 5 days

10 mg

(1.4 to 1.7)

(1.8 to 2.3)

Darunavir 600 mg/ritonavir 100 mg BID, 7

days

10 mg QD for 7

days

(1.0 to 2.1)

(1.6 to 3.6)

Tipranavir/ritonavir combination 500 mg/200

mg BID for 11 days

10 mg

(1.2 to 1.6)

(1.8 to 2.7)

Dronedarone 400 mg BID

10 mg

Itraconazole 200 mg QD, 5 days

10 mg or

80 mg

(1.2 to 1.6)

(1.1 to 1.4)

(1.2 to 1.5)

(0.9 to 1.4)

Ezetimibe 10 mg QD, 14 days

10 mg QD for 14

days

(0.9 to1.6)

(0.8 to 1.6)

Fosamprenavir/ritonavir

700 mg/100 mg BID for 7 days

10 mg

1

max

2

2

2

2

2

3

2

3

2

3

2

3

2

2

3

3

3

3

3

3

3

3

3

3

3

3

3

Single dose unless otherwise noted.

Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)]

Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease,

11=11 fold increase in exposure)

Fenofibrate 67 mg TID for 7 days

10 mg

(1.1 to 1.3)

Rifampicin 450 mg QD, 7 days

20 mg

Aluminum & magnesium hydroxide

combination antacid

Administered simultaneously

Administered 2 hours apart

40 mg

40 mg

(0.4 to 0.5)

(0.7 to 0.9)

(0.4 to 0.6)

(0.7 to 1.0)

Ketoconazole 200 mg BID for 7 days

80 mg

(0.8 to 1.2)

(0.7 to 1.3)

Fluconazole 200 mg QD for 11 days

80 mg

(1.0 to 1.3)

(0.9 to 1.4)

Erythromycin 500 mg QID for 7 days

80 mg

(0.7 to 0.9)

(0.5 to 0.9)

Table 5. Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs

EE = ethinyl estradiol, NG = norgestrel

Clinically significant pharmacodynamic effects [see Warnings and Precautions (5.3)]

Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease,

11=11-fold increase in exposure)

Rosuvastatin Dosage

Regimen

Coadministered Drug

Mean Ratio

(ratio with/without

coadministered drug)

No Effect = 1.0

Name and Dose

Change in AUC

Change in C

40 mg QD for 10 days

Warfarin

25 mg single dose

R-Warfarin

(1.0 to 1.1)

S-Warfarin 1.1

(1.0 to 1.1)

R-Warfarin

(0.9 to 1.0)

S-Warfarin

(0.9 to 1.1)

40 mg QD for 12 days

Digoxin

0.5 mg single dose

(0.9 to 1.2)

(0.9 to 1.2)

40 mg QD for 28 days

Oral Contraceptive

(ethinyl estradiol 0.035 mg &

norgestrel 0.180, 0.215 and

0.250 mg) QD for 21 Days

EE 1.3

(1.2 to 1.3)

NG 1.3

(1.3 to 1.4)

EE 1.3

(1.2 to 1.3)

NG 1.2

(1.1 to 1.3)

12.5 Pharmacogenomics

Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and other

transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small

groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1

( SLCO1B1 521T > C). The frequency of this genotype (i.e., SLCO1B1 521 C/C) is generally lower than

5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of

rosuvastatin has not been clearly established.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

3

2

3

3

2

3

3

3

3

3

3

3

3

max

1

2

2

2

2

2

2

2

2

2

2

In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage,

the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at

systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of

polyps was not seen at lower doses.

In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an

increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic

exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of

hepatocellular tumors was not seen at lower doses.

Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test

with Salmonella typhimurium and Escherichia coli, the mouse lymphoma assay, and the chromosomal

aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the in vivo mouse

micronucleus test.

In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks

prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating

until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures

up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with

rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells

were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of

seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the

human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other

drugs in this class.

13.2 Animal Toxicology and/or Pharmacology

Central Nervous System Toxicity

CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell

infiltration of perivascular spaces, have been observed in dogs treated with several other members of

this drug class. A chemically similar drug in this class produced dose-dependent optic nerve

degeneration (Wallerian degeneration of retinogeniculate fibers) in dogs, at a dose that produced

plasma drug levels about 30 times higher than the mean drug level in humans taking the highest

recommended dose. Edema, hemorrhage, and partial necrosis in the interstitium of the choroid plexus

was observed in a female dog sacrificed moribund at day 24 at 90 mg/kg/day by oral gavage (systemic

exposures 100 times the human exposure at 40 mg/day based on AUC). Corneal opacity was seen in

dogs treated for 52 weeks at 6 mg/kg/day by oral gavage (systemic exposures 20 times the human

exposure at 40 mg/day based on AUC). Cataracts were seen in dogs treated for 12 weeks by oral

gavage at 30 mg/kg/day (systemic exposures 60 times the human exposure at 40 mg/day based on AUC).

Retinal dysplasia and retinal loss were seen in dogs treated for 4 weeks by oral gavage at 90 mg/kg/day

(systemic exposures 100 times the human exposure at 40 mg/day based on AUC). Doses ≤ 30 mg/kg/day

(systemic exposures ≤ 60 times the human exposure at 40 mg/day based on AUC) did not reveal retinal

findings during treatment for up to one year.

Juvenile Toxicology Study

In a juvenile study, rats were dosed by oral gavage with 10 or 50 mg/kg/day from weaning for 9

weeks prior to pairing, throughout pairing and up to the day before necropsy for males or up to

gestation day 7 for females. No effects on sexual development, testicular and epididymal appearance or

fertility were observed at either dose level.

Pediatric information is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets.

However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled

with that pediatric information.

14 CLINICAL STUDIES

14.3 Hypertriglyceridemia

Dose-Response Study: In a double-blind, placebo-controlled dose-response study in patients with

baseline TG levels from 273 to 817 mg/dL, rosuvastatin calcium given as a single daily dose (5 to 40

mg) over 6 weeks significantly reduced serum TG levels (Table 9).

Table 9. Dose-Response in Patients with Primary Hypertriglyceridemia over 6 Weeks Dosing Median (Min, Max)

Percent Change from Baseline

Dos e

Placebo (n=26)

Rosuvastatin

5 mg

(n=25)

Rosuvastatin

10 mg

(n=23)

Rosuvastatin

20 mg

(n=27)

Rosuvastatin

40 mg

(n=25)

Triglycerides

1 (-40, 72)

-21 (-58, 38)

-37 (-65, 5)

-37 (-72, 11)

-43 (-80, -7)

nonHDL-C

2 (-13, 19)

-29 (-43, -8)

-49 (-59, -20)

-43 (-74, 12)

-51 (-62, -6)

VLDL-C

2 (-36, 53)

-25 (-62, 49)

-48 (-72, 14)

-49 (-83, 20)

-56 (-83, 10)

Total-C

1 (-13, 17)

-24 (-40, -4)

-40 (-51, -14)

-34 (-61, -11)

-40 (-51, -4)

LDL-C

5 (-30, 52)

-28 (-71, 2)

-45 (-59, 7)

-31 (-66, 34)

-43 (-61, -3)

HDL-C

-3 (-25, 18)

3 (-38, 33)

8 (-8, 24)

22 (-5, 50)

17 (-14, 63)

14.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

In a randomized, multicenter, double-blind crossover study, 32 patients (27 with ε2/ε2 and 4 with apo E

mutation [Arg145Cys] with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia) entered a

6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following

dietary lead-in, patients were randomized to a sequence of treatments in conjunction with the TLC diet

for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed

by rosuvastatin 10 mg. Rosuvastatin reduced non HDL-C (primary end point) and circulating remnant

lipoprotein levels. Results are shown in the table below.

Table 10. Lipid-modifying Effects of Rosuvastatin 10 mg and 20 mg in Primary

Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent

Change (95% CI) from Baseline (N=32)

Median at Baseline

(mg/dL)

Median percent change

from baseline (95% CI)

Rosuvastatin 10 mg

Median percent change

from baseline (95% CI)

Rosuvastatin 20 mg

Total-C

342.5

-43.3

(-46.9, -37.5)

-47.6

(-51.6, -42.8)

Triglycerides

503.5

-40.1

(-44.9, -33.6)

-43.0

(-52.5, -33.1)

NonHDL-C

294.5

-48.2

(-56.7, -45.6)

-56.4

(-61.4, -48.5)

VLDL-C + IDL-C

209.5

-46.8

(-53.7, -39.4)

-56.2

(-67.7, -43.7)

LDL-C

112.5

-54.4

(-59.1, -47.3)

-57.3

(-59.4, -52.1)

HDL-C

35.5

10.2

(1.9, 12.3)

11.2

(8.3, 20.5)

RLP-C

82.0

-56.4

(-67.1, -49.0)

-64.9

(-74.0, -56.6)

Apo-E

16.0

-42.9

(-46.3, -33.3)

-42.5

(-47.1, -35.6)

14.5 Homozygous Familial Hypercholesterolemia

Dose-Titration Study: In an open-label, forced-titration study, homozygous FH patients (n=40, 8 to 63

years) were evaluated for their response to rosuvastatin 20 to 40 mg titrated at a 6-week interval. In the

overall population, the mean LDL-C reduction from baseline was 22%. About one-third of the patients

benefited from increasing their dose from 20 mg to 40 mg with further LDL lowering of greater than

6%. In the 27 patients with at least a 15% reduction in LDL-C, the mean LDL-C reduction was 30%

(median 28% reduction). Among 13 patients with an LDL-C reduction of <15%, 3 had no change or an

increase in LDL-C. Reductions in LDL-C of 15% or greater were observed in 3 of 5 patients with

known receptor negative status.

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

16 HOW SUPPLIED/STORAGE AND HANDLING

Rosuvastatin Tablets USP 5 mg are pink, oval shaped, biconvex film-coated tablets debossed with ‘I’

on one side and ‘29’ on the other side.

Bottles of 30 NDC 57237-168-30

Bottles of 90 NDC 57237-168-90

Bottles of 500 NDC 57237-168-05

Bottles of 1,000 NDC 57237-168-99

Rosuvastatin Tablets USP 10 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on

one side and ‘30’ on the other side.

Bottles of 30 NDC 57237-169-30

Bottles of 90 NDC 57237-169-90

Bottles of 500 NDC 57237-169-05

Bottles of 1,000 NDC 57237-169-99

Rosuvastatin Tablets USP 20 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on

one side and ‘31’ on the other side.

Bottles of 30 NDC 57237-170-30

Bottles of 90 NDC 57237-170-90

Bottles of 500 NDC 57237-170-05

Bottles of 1,000 NDC 57237-170-99

Rosuvastatin Tablets USP 40 mg are pink, oval shaped, biconvex film-coated tablets debossed with

‘I’ on one side and ‘32’ on the other side.

Bottles of 30 NDC 57237-171-30

Bottles of 90 NDC 57237-171-90

Bottles of 500 NDC 57237-171-05

Bottles of 1,000 NDC 57237-171-99

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP

Controlled Room Temperature]. Protect from moisture.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Patients should be instructed not to take 2 doses of rosuvastatin within 12 hours of each other.

Skeletal Muscle Effects

Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness,

particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after

discontinuing rosuvastatin.

Concomitant Use of Antacids

When taking rosuvastatin with an aluminum and magnesium hydroxide combination antacid, the antacid

should be taken at least 2 hours after rosuvastatin administration.

Embryofetal Toxicity

Advise females of reproductive potential of the risk to a fetus, to use effective contraception during

treatment, and to inform their healthcare provider of a known or suspected pregnancy. [see

Contraindications (4) and Use in Specific Populations (8.1, 8.3)].

Lactation

Advise women not to breastfeed during treatment with rosuvastatin [see Contraindications (4) and Use in

Specific Populations (8.2)].

Liver Enzymes

It is recommended that liver enzyme tests be performed before the initiation of rosuvastatin and if signs

or symptoms of liver injury occur. All patients treated with rosuvastatin should be advised to promptly

report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal

discomfort, dark urine or jaundice.

CRESTOR is a trademark of the AstraZeneca group of companies.

Distributed by:

Rising Health, LLC

Saddle Brook, NJ 07663

Made in India

Code: TS/DRUGS/19/1993

Revised: 12/2018

PATIENT INFORMATION

Rosuvastatin Tablets USP

(roe-SOO-va-STAT-in)

Read this Patient Information carefully before you start taking rosuvastatin tablets and each time you get

a refill. If you have any questions about rosuvastatin tablets, ask your doctor. Only your doctor can

determine if rosuvastatin tablets are right for you.

What are rosuvastatin tablets?

Rosuvastatin tablets are a prescription medicine that contains a cholesterol-lowering medicine called

rosuvastatin calcium. Most of the cholesterol in your blood is made in the liver. Rosuvastatin tablets

work by reducing cholesterol in two ways: rosuvastatin tablets block an enzyme in the liver causing the

liver to make less cholesterol, and rosuvastatin tablets increase the uptake and breakdown by the liver of

cholesterol already in the blood.

Rosuvastatin tablets are used along with diet to:

○ lower the level of your “bad” cholesterol (LDL)

○ increase the level of your “good” cholesterol (HDL)

○ lower the level of fat in your blood (triglycerides)

Rosuvastatin tablets are used to treat:

○ adults who cannot control their cholesterol levels by diet and exercise alone

It is not known if rosuvastatin tablets are safe and effective in people who have Fredrickson Type I and

V dyslipidemias.

Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s

CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity

rights, this drug product is not labeled with that pediatric information.

Who should not take rosuvastatin tablets?

Do not take rosuvastatin tablets if you:

are allergic to rosuvastatin calcium or any of the ingredients in rosuvastatin tablets. See the end of

this leaflet for a complete list of ingredients in rosuvastatin tablets.

have liver problems.

are pregnant or think you may be pregnant, or are planning to become pregnant. Rosuvastatin tablets

may harm your unborn baby. If you become pregnant, stop taking rosuvastatin tablets and call your

doctor right away. If you are not planning to become pregnant you should use effective birth control

(contraception) while you are taking rosuvastatin tablets.

are breastfeeding. Medicines like rosuvastatin calcium can pass into your breast milk and may harm

your baby.

What should I tell my doctor before and while taking rosuvastatin tablets?

Tell your doctor if you:

have unexplained muscle aches or weakness

have or have had kidney problems

have or have had liver problems

drink more than 2 glasses of alcohol daily

have thyroid problems

are 65 years of age or older

are of Asian descent

are pregnant or think you may be pregnant, or are planning to become pregnant

are breastfeeding

Tell your doctor about all the medicines you take, including prescription and over-the-counter

medicines, vitamins, and herbal supplements.

Talk to your doctor before you start taking any new medicines.

Taking rosuvastatin tablets with certain other medicines may affect each other causing side effects.

Rosuvastatin tablets may affect the way other medicines work, and other medicines may affect how

rosuvastatin tablets work.

Especially tell your doctor if you take:

cyclosporine (a medicine for your immune system)

gemfibrozil (a fibric acid medicine for lowering cholesterol)

anti-viral medicines including HIV or hepatitis C protease inhibitors (such as lopinavir, ritonavir,

fosamprenavir, tipranavir, atazanavir, or simeprevir)

certain anti-fungal medicines (such as itraconazole, ketoconazole and fluconazole)

coumarin anticoagulants (medicines that prevent blood clots, such as warfarin)

niacin or nicotinic acid

fibric acid derivatives (such as fenofibrate)

colchicine (a medicine used to treat gout)

Ask your doctor or pharmacist for a list of these medicines if you are not sure.

Know all of the medicines you take. Keep a list of them to show your doctor and pharmacist when you

get new medicine.

How should I take rosuvastatin tablets?

Take rosuvastatin tablets exactly as your doctor tells you to take them.

Take rosuvastatin tablets, by mouth, 1 time each day. Swallow the tablet whole.

Rosuvastatin tablets can be taken at any time of day, with or without food.

Do not change your dose or stop rosuvastatin tablets without talking to your doctor, even if you are

feeling well.

Your doctor may do blood tests to check your cholesterol levels before and during your treatment

with rosuvastatin tablets. Your doctor may change your dose of rosuvastatin tablets if needed.

Your doctor may start you on a cholesterol lowering diet before giving you rosuvastatin tablets.

Stay on this diet when you take rosuvastatin tablets.

Wait at least 2 hours after taking rosuvastatin tablets to take an antacid that contains a combination of

aluminum and magnesium hydroxide.

If you miss a dose of rosuvastatin tablets, take it as soon as you remember. However, do not take 2

doses of rosuvastatin tablets within 12 hours of each other.

If you take too much rosuvastatin calcium or overdose, call your doctor or go to the nearest hospital

emergency room right away.

What are the Possible Side Effects of Rosuvastatin Tablets?

Rosuvastatin tablets may cause serious side effects, including:

Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle

breakdown, can be serious in some people and rarely cause kidney damage that can lead to death.

Tell your doctor right away if:

you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever

or feel more tired than usual, while you take rosuvastatin tablets.

you have muscle problems that do not go away even after your doctor has told you to stop taking

rosuvastatin tablets. Your doctor may do further tests to diagnose the cause of your muscle

problems.

Your chances of getting muscle problems are higher if you:

are taking certain other medicines while you take rosuvastatin tablets

are 65 years of age or older

have thyroid problems (hypothyroidism) that are not controlled

have kidney problems

are taking higher doses of rosuvastatin tablets

Liver problems. Your doctor should do blood tests to check your liver before you start taking

rosuvastatin tablets and if you have symptoms of liver problems while you take rosuvastatin tablets.

Call your doctor right away if you have any of the following symptoms of liver problems:

feel unusually tired or weak

loss of appetite

upper belly pain

dark urine

yellowing of your skin or the whites of your eyes

The most common side effects may include: headache, muscle aches and pains, abdominal pain,

weakness, and nausea.

Additional side effects that have been reported with rosuvastatin tablets include memory loss and

confusion.

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of rosuvastatin tablets. For more information, ask your doctor

or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-

800-FDA-1088.

How should I store rosuvastatin tablets?

Store rosuvastatin tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to

86°F) [see USP Controlled Room Temperature] and in a dry place.

Safely throw away medicine that is out of date or no longer needed.

Keep rosuvastatin tablets and all medicines out of the reach of children.

What are the Ingredients in rosuvastatin tablets?

Active Ingredient: rosuvastatin as rosuvastatin calcium

Inactive Ingredients: crospovidone, dibasic calcium phosphate anhydrous, hypromellose, iron oxide

red, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide, and

triacetin.

General Information about the safe and effective use of rosuvastatin tablets

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

Do not use rosuvastatin tablets for a condition for which it was not prescribed. Do not give rosuvastatin

tablets to other people, even if they have the same medical condition you have. They may harm them.

You can ask your pharmacist or doctor for information about rosuvastatin tablets that is written for

health professionals.

CRESTOR is a trademark of the AstraZeneca group of companies.

Distributed by:

Rising Health, LLC

Saddle Brook, NJ 07663

Made in India

Code: TS/DRUGS/19/1993

Revised: 12/2018

For more information, call Rising Health, LLC at 1-833-395-6928.

This Patient Information has been approved by the U.S. Food and Drug Administration.

DRUG: Rosuvastatin Calcium

GENERIC: Rosuvastatin Calcium

DOSAGE: TABLET, FILM COATED

ADMINSTRATION: ORAL

NDC: 70518-0002-0

COLOR: pink

SHAPE: ROUND

SCORE: No score

SIZE: 7 mm

IMPRINT: I;31

PACKAGING: 90 in 1 BOTTLE, PLASTIC

ACTIVE INGREDIENT(S):

ROSUVASTATIN CALCIUM 20mg in 1

INACTIVE INGREDIENT(S):

CROSPOVIDONE

MICROCRYSTALLINE CELLULOSE

MAGNESIUM STEARATE

TITANIUM DIOXIDE

LACTOSE MONOHYDRATE

ANHYDROUS DIBASIC CALCIUM PHOSPHATE

FERRIC OXIDE RED

HYPROMELLOSE 2910 (15 MPA.S)

TRIACETIN

ROSUVASTATIN CALCIUM

rosuvastatin calcium tablet, film coated

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:70 518 -0 0 0 2(NDC:57237-170 )

Route of Administration

ORAL

REMEDYREPACK INC.

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

RO SUVASTATIN CALCIUM (UNII: 8 3MVU38 M7Q) (ROSUVASTATIN - UNII:413KH5ZJ73)

ROSUVASTATIN

20 mg

Inactive Ingredients

Ingredient Name

Stre ng th

CRO SPO VIDO NE (UNII: 6 8 40 19 6 0 MK)

ANHYDRO US DIBASIC CALCIUM PHO SPHATE (UNII: L11K75P9 2J)

HYPRO MELLO SE 2 9 10 ( 15 MPA.S) (UNII: 36 SFW2JZ0 W)

FERRIC O XIDE RED (UNII: 1K0 9 F3G6 75)

LACTO SE MO NO HYDRATE (UNII: EWQ57Q8 I5X)

MAGNESIUM STEARATE (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)

TRIACETIN (UNII: XHX3C3X6 73)

Product Characteristics

Color

pink

S core

no sco re

S hap e

ROUND (Bico nvex)

S iz e

Flavor

Imprint Code

I;31

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:70 518 -0 0 0 2-0

9 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

11/16 /20 16

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 79 170

11/16 /20 16

Labeler -

REMEDYREPACK INC. (829572556)

Revised: 2/2020

Similar products

Search alerts related to this product

Share this information